Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.

Abstract

Background: Recently, high response rates have been reported in patients with advanced gastric cancer with a schedule of epirubicin, cisplatin, and protracted infusion of 5-fluorouracil (5-FU). We modified this schedule based on the assumption that shorter treatment intervals are more convenient for patients and that cytokinetically based data showed that most gastric cancers have a relatively short potential doubling time of of less than 14 days.

Patients and methods: Fourteen patients with advanced gastric adenocarcinoma with progressive, measurable disease entered the study. Patients were treated from days 1 to 14 with 5-FU 200 mg/m2 per day as a continuous infusion using a portable infusion pump. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered on day 1. Courses were repeated every 4 weeks.

Results: No responses were observed (response rate 0% [95% CI 0-23%]). Toxicity was mild. Grade 3 toxicity occurred in only 2 patients (14%). The median progression free survival was 3.5 months (range 2 to 17). The median survival was 6.5 months (range 2 to 31+).

Conclusions: The unexpected results of this study are most likely due to a diminished dose intensity. When comparing the results of several schedules with epirubicin, cisplatin, and 5-FU, it seems that the dose intensity for all three drugs may be important, but especially for 5-FU.